FRFu-Meei Robbins

Fu-Meei Robbins

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fu-Meei Robbins has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • CD31/PECAM-1 genotyping and haplotype analyses show population diversity

    by F.-M. Robbins, R. J. Hartzman

    Using direct sequencing of complementary DNA products, the sequences of human CD31 from exon 1 through exon 16 of 179 individuals (139 unrelated) were systematically examined. Of the 14 biallelic single nucleotide polymorphic sites detected, 7 polymorphic sites involved amino acid substitution. These 14 polymorphic sites yielded 18 observed CD31 alleles and 9 predicted CD31 polypeptide sequences. Based on molecular haplotyping and family pedigree analysis, linkage disequilibrium among some single nucleotide polymorphic sites was observed. Single nucleotide polymorphism frequencies between populations were also measured using dot-blot hybridization with DNA or peptide nucleic acid probes.


  • Open Access

    HLA class I and II genotype of the NCI-60 cell lines

    by Sharon Adams, Fu-Meei Robbins, Deborah Chen, Devika Wagage, Susan L Holbeck, Herbert C Morse, David Stroncek, Francesco M Marincola

    Sixty cancer cell lines have been extensively characterized and used by the National Cancer Institute's Developmental Therapeutics Program (NCI-60) since the early 90's as screening tools for anti-cancer drug development. An extensive database has been accumulated that could be used to select individual cells lines for specific experimental designs based on their global genetic and biological profile. However, information on the human leukocyte antigen (HLA) genotype of these cell lines is scant and mostly antiquated since it was derived from serological typing. We, therefore, re-typed the NCI-60 panel of cell lines by high-resolution sequence-based typing. This information may be used to: 1) identify and verify the identity of the same cell lines at various institutions; 2) check for possible contaminant cell lines in culture; 3) adopt individual cell lines for experiments in which knowledge of HLA molecule expression is relevant. Since genome-based typing does not guarantee actual surface protein expression, further characterization of relevant cell lines should be entertained to verify surface expression in experiments requiring correct antigen presentation.


    • 1 February 1987
      • Vol. 19, 842-4

    DR3 heterogeneity recognized by HTC and alloproliferative T cell clones.

    by S Rosen-Bronson, T F Tang, D D Eckels, F M Robbins, G Dunston, R J Hartzman, A H Johnson